Up until last week i defended the board against much of the criticism they faced. However looking back at the interview on 02 October and the sells before the rns I smell a rat.
. In the near to medium term, we expect the primary value driver for Sareum to remain SDC-1801, with key inflection points likely to arise from the completion of toxicology studies for Phase II and the subsequent initiation of the trial.